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Background: Chronic Heart Failure is a major health problem with a prevalence of between 1 and 12% in USA and 
Europe, and approximately 5.7% in Sub-Saharan Africa, and has socio-economic relevance owing to its high 
prevalence, mortality and impact on young economically active individuals. In 1999 chronic heart failure constituted 
3.3% of all medical admissions at Kenyatta National Hospital.  
Objective: The purpose of the current study was to determine factors that affect adherence to treatment among 
patients with Chronic Heart Failure at Kenyatta National Hospital and assess any association between any such factors 
Methodology: This was a descriptive cross-sectional study involving patients >18 years diagnosed with Chronic 
Heart Failure at Kenyatta National Hospital. Eighty three eligible and consenting study participants were recruited 
into the study using a convenient sampling technique. Data were collected by means of an interviewer administered 
questionnaire adapted from the Revised HF Adherence Questionnaire.   
Results: Data from 83 patients was analyzed majority (n=51, 61.4%) of whom were women. The age of the patients 
ranged from 18 to 80 years with the majority (n= 37, 44.6%), between 21-40 years. Majority (n=58, 68.9%) of the 
patients considered appointment keeping, compliance to medication (n= 64, 77.1%), dietary restriction (n=59, 72%), 
regular exercise (n=49 59.0%), smoking cessation (n=59, 71%), and alcohol cessation (n=58, 69.9%) as very 
important. Fifty three (63.9%) respondents had not failed to take their medicines at any time.  Majority (n=72, 86.8%) 
of the study participants were aware of the disease condition they were suffering from while valvular heart disease 
was the commonest comorbidity (n= 17 27.9%). The study revealed an association between sex and some adverse 
drug reactions using Pearson χ² test through bivariate analysis. Sleep disturbances and nausea occurred more in 
males than females while headache and drowsiness were more prevalent in females and in both cases the 
relationships were statistically significant (p< 0.05) 
Conclusions: Adherence to medicines among patients with Chronic Heart Failure is reasonably high at Kenyatta 
National Hospital despite patients’ knowledge level about the condition being generally low. Valvular heart disease 
was the most common comorbidity while hyponatremia was the most prevalent electrolyte disturbance, and 
tachycardia, vomiting and rash the most common adverse drug effects.  
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1. Introduction 
Chronic heart failure (CHF) is a clinical condition in 
which the heart is unable to provide adequate blood for 
the metabolic needs of the body (Whang et al, 2013). 
This is characterized by shortness of breath and fatigue 
at rest or with exertion in the presence of underlying 
structural and/or functional heart disease which results 
in diminished ability to increase cardiac output or 
cardiac work in response to an increase in pre-load 
(Katz et al, 2009).  
Although the hemodynamic abnormalities may explain 
the symptoms of CHF, they do not adequately explain 
the disease progression and researchers have reported 
that activation of the sympathetic and the Renin 
Angiotensin Aldosterone System (RAAS) exerts a direct 
deleterious effect on the heart that is independent of 
their hemodynamic effects, and interventions targeting 
these neurohumoral systems favorably alter the natural 
history of the disease (Packer et al, 1999).Other 
researchers have similarly reported that the interplay 
between diverse organ systems contributing to CHF is 
mediated by the activation of various counteracting 
neurohormonal pathways geared to re-establishing 
hemodynamic homeostasis(Buglioni et al, 2015). 
The exact prevalence of CHF is currently estimated to be 
between 1% and 12% in USA and Europe.  Mann et al, 
2008 estimated a prevalence of 2% and rising while in 
an earlier study, Mosterd et al, 1998 had estimated the 
overall prevalence to be 3.9%.  Tantchou et al, 2011, in a 
study to determine occurrence, etiology and challenges 
in the management of CHF reported an occurrence of 
5.7%, while among all admissions at Kenyatta National 
Hospital (KNH), CHF constituted 3.3% of cases and 
rheumatic heart disease was the commonest cause 
(Oyoo et al, 1999). Recent studies indicate that although 
CHF is still predominantly non-ischemic, coronary heart 
disease has assumed greater prominence in the last 15 
years (Ogeng’o et al, 2014).The disease is the leading 
cause of hospitalization in patients over 65 years and 
represents a significant clinical and economic burden 
(Azad et al, 2014).   
There is need for the healthcare professional to be 
equipped with the knowledge and tools to assure 
comprehensive care not only addressing the heart 
failure, but the individual as a whole  especially the 
older patients (Azad et al, 2014). The patients also need 
to be informed of the complexity of the management 
regimens and the importance of adherence to the 
management plans. 
Patients fail to adhere to medicines due to several 
reasons including, adverse effects of drugs, 
forgetfulness, and inadequate communication between 
the healthcare provider and the patient, emotional 
factors, occupation, cost of the medications and poor 
accessibility to prescribed medicines. These barriers to 
adherence could be the result of complex regimens, 
failure of the healthcare provider to adequately explain 
the benefits and adverse effects of the medicines, as 
well as failure to take into consideration the patient’s 
occupation or the cost of the drugs, and a poor 
therapeutic relationship between healthcare provider 
and the patient. Non-adherence to a therapeutic 
regimen may result in negative outcomes and may be 
compounded in patients with multiple comorbidities 
which require multiple drug therapy (Hughes et al, 
2004). 
Non-adherence to medications, diet and fluid restriction 
in management of CHF decreases the efficacy of 
prescribed treatment and exposes the patient to clinical 
destabilization, which can lead to worsening of CHF 
symptoms (Hughes et al, 2004). Thus non-adherence 
may result in: poor clinical outcomes, poor health 
related quality of life and additional economic burden to 
the healthcare system. 
While data on adherence is available in developed 
countries, there is paucity of data from local studies 
conducted in the developing countries. The purpose of 
the study was to determine the factors that affect 
adherence to medicines among patients with CHF at 
KNH and assess any association between any such 
factors 
2. Methodology 
2.1 Study design 
The study design was descriptive cross-sectional. The 
purpose of the current study was to descriptively shed 
light on the factors affecting adherence among patients 
with CHF attending the cardiology clinic as well as those 
admitted in KNH with the condition.  
2.2 Study area 
This study was carried out at Kenyatta National 
Hospital (KNH). The hospital conducts a cardiology 
clinic once a week with approximately 80 patients per 
clinic day and an average of 30 new patients per month. 
KNH is a Teaching and National Referral Hospital with a 
bed capacity of 1800. Its choice as the study site was 
based on the availability of a sizeable number patients 
presenting with CHF. 
2.3 Study population 
The study population was patients aged above 18 years 
presenting with CHF admitted into Kenyatta National 
Hospital and those attending the cardiology clinic. 
Eligibility criteria 
Consenting male and female patients above the age of 
18 years diagnosed with CHF were included in the 
study, while uncooperative patients due to dementia or 
psychosis and patients unable to participate in the 
study due to their disease condition were excluded.  
2.4 Sampling 
The sample size was determined using the Fisher and 
Van Bell formula (Le, 2003), applying the estimated 
prevalence of 5.7% (Tantchou et al, 2011). 
Eighty three participants who meet the inclusion 
criteria were recruited into the study using convenient 
sampling. 
2.5 Data collection 
An interviewer administered questionnaire adapted 
from the Revised HF adherence Questionnaire was used 
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for purposes of collecting demographic data, responses 
with respect to adherence, level of knowledge about 
CHF, and types of adverse drug reactions experienced 
while on treatment for CHF (van der Wal et al, 2006).  
Patients file records were reviewed to capture clinical 
data, treatment regimen, comorbidities associated with 
CHF, blood urea, creatinine and electrolyte levels. 
2.6 Data analysis 
Data were coded to ensure confidentiality, entered into 
the data base and double checked to ensure accuracy 
and cleaning. Descriptive data analysis was carried out 
on all variables using STATA V.12.   
Bivariate analysis was used to establish the association 
between each of the predictor variables and the 
dependent variable, and multivariable regression to 
establish the association between several variables 
using a linear regression model. 
2.7 Ethical considerations 
Approval (KNH-ERC/A/396) was obtained from the 
Kenyatta National Hospital/University of Nairobi Ethics 
and Research Committee (KNH/UON-ERC), before the 
commencement of the study.  
3.  Results 
3.1 Sociodemographic characteristics  
Among 83 respondents, 51(61.4%) were female, and 
the age of the patients ranged from 18 to 80 years with 
the majority (n= 37, 44.6%), between 21-40 years, an 
important economically active age group.    
Sixty one (73.5%), were married, and only 17(20.5%) 
had attained tertiary level of education.  
Majority (n=38, 45.8%) were self-employed and 17 
(20.7%) admitted having taken alcohol at some point in 
their lives and of those 17, 8 (47.1%), had taken it for 
more than 10 years. Thirteen (15.7%) reported having 
smoked at some point in their lives. 
3.2 The proportion of patients with CHF that 
adhere to drugs  
Indicators of adherence to management protocol 
Patients were requested to report on their adherence to 
management protocol through several questions on the 
various indicators of adherence; these included follow-
up with appointments, medication compliance, dietary 
restrictions, regular exercise, smoking cessation and 
alcohol cessation (Table 1). Majority (n=58, 68.9%) of 
the patients considered follow-up, acquiescence to 
medication (n= 64, 77.1%), dietary restriction (n=59, 
72%), regular exercise (n=49, 59.0%), smoking 
cessation (n=59, 71.0%), and alcohol cessation (n=58, 
69.9%) as very important. Between 0-1.2% considered 
these indicators as not important. 
Non-adherence to medicines 
Majority (n=53, 63.9%) of study participants reported 
having not failed to comply in taking their medicines at 
any time, with 28(33.7%) reporting having failed to 
take their medicine rarely, while 1(1.2%) reported 
having failed to take his medicines most of the time 
(Table 2). Seventeen (60.7%) of the respondents failed 
to take their medicine due to forgetfulness while 6(21.4 
%) was because the instructions were too complicated. 
Accessibility to medicines 
Sixty eight (81.9%) of the respondents had no difficulty 
obtaining medicines prescribed for them while 15 
(18.1%) found it difficult. Sixty three (75.9%) of the 
study participants had been informed by the healthcare 
provider as to why they were taking the prescribed 
medicines, while 20 (24.1%) denied having received 
such a communication. 
3.3 Drugs prescribed for patients with CHF  
Seventy five (90.4%) of the study participant were on a 
diuretic, while 45 (54.2%) were on a β-adrenergic 
receptor antagonist.   The most commonly prescribed 
drug combination was, a diuretic + ACE inhibitor + β-
blocker+ cardiac glycoside (n=15, 19.0%). 
   Table 1: Indicators of adherence to management protocol 
Indicator 
Not important 
n (%) 
Not very important 
n (%) 
Important 
n (%) 
Very important 
n (%) 
Follow up 1 (1.2%) 2 (2.4%) 22(26.5%) 58 (68.9%) 
Medication 0 (0%) 1(1.2%) 18 (21.7%) 64(77.1%) 
Diet restrictions  1(1.2%) 3(3.7%) 19(23.2%) 59(72.0%) 
Regular exercise  2(2.4%) 10(12.1%) 22(26.5%) 49(59.0%) 
Smoking cessation 0 (0%) 2 (2.4%) 22(26.5%) 59 (71.0) 
Alcohol cessation 1(1.4%) 1(1.2%) 23(27.7%) 58 (69.9%) 
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      Table 2: Non-adherence to required use of medicines 
Characteristic Frequency (n) Percentage (%) 
Failure to take  medicines   
Most of the time 1 1.2 
Half the time 1 1.2 
Rarely  28 33.7 
None of the time 53 63.9 
Reasons for failing to take medicines   
Side effects 1 3.6 
Frequency of dosing  1 3.6 
Medicines not working 1 3.6 
Forgetfulness  17 60.7 
Instructions are too complicated 6 21.4 
Too many drugs 2 7.1 
 
      Table 3: Relationship between sex and adverse drug reactions 
Adverse drug reaction Males (n, %) Females (n, %) P-value 
Sleep disturbances    
Yes 13(15.7%) 10(12%) 0.037 
No 19(22.9%) 41(49.4%  
Headache    
Yes 9(10.8%) 27(32.5%) 0.026 
No 23(27.7%) 24(28.9%)  
Drowsiness    
Yes 6(7.2%) 28(33.7%) 0.001 
No 26(31.3%) 23(27.7%)  
Nausea    
Yes 13(15.7%) 9(10.8%) 0.021 
No 19(22.9%) 42(50.6%)  
 
3.4 Patient knowledge about CHF 
Majority (n=72, 86.8%) of the study participants were 
aware of the disease condition they were suffering from 
and 65(85.5%) had suffered from the condition for less 
than 5 years. 
Fifty one (61.4%) had been admitted to a hospital for 
the condition, and of those who had been admitted to 
hospital, 18(35.8%) had been admitted once. While 
40(48.2%) participants had been advised on the 
expected outcome of their condition 43(51.8%) were 
not aware of the outcome. Fifty six (67.5%) had been 
advised on lifestyle changes requisite to ensure that 
symptoms of CHF did not worsen and 29(34.9%) of the 
respondents understood a little regarding the requisite 
lifestyle changes. 
3.5 Comorbidities associated with CHF 
Valvular heart disease (VHD) presented as the 
commonest comorbidity (n=17, 27.9%) in patients with 
CHF.  
3.6 Prevalence of adverse drug reactions used in 
the treatment of CHF 
Fifty six (67.5%) of the study participants experienced 
tachycardia, while 54(65.1%) skin rash and 48(57.8%) 
vomiting during the course of treatment for CHF.  
Others experienced various adverse drug reactions as 
shown in Table 3. 
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3.7 Serum levels of blood urea, creatinine and 
electrolytes  
Majority (n=43, 51.8%) of the participants were 
hyponatremic and 11 (13.3%) had elevated levels of 
potassium. Twelve (14.5%) had elevated urea levels, 
and 10(12%) had elevated creatinine levels. 
3.8 Association between sex and adverse drug 
reactions 
Our study revealed a relationship between sex and 
some adverse drug reactions using Pearson chi square 
test through bivariate analysis (Table 3). Sleep 
disturbances and nausea occurred more in males than 
females while headache and drowsiness were more 
prevalent in females. Among the side effects explored 
less than half of the patients experienced them. 
4. Discussion 
The prevalence of CHF is slightly higher among women 
than men which does not concur with an earlier study 
by Ogeng’o et al, 2014 which reported a male:female 
ratio of 1:1 without a difference in age groups. Majority 
of the study participants were between 21-40 years, 
which is an important economically active age group 
(Tantchou et al, 2011). This shows an earlier onset of 
CHF compared to Caucasian populations probably due 
to the fact that the predominant cause of CHF in the 
Kenyan population is still rheumatic heart disease 
(Oyoo et al, 1999, Ogeng’o et al, 2014). 
Adherence has been defined as the extent to which the 
patient’s medication taking behavior corresponds with 
an agreed upon medication regimen (Riegel et al, 2012). 
This entails taking the correct medicine, the correct 
dose, at the right time, and avoiding missing a dose for 
more than a specified period of time. The six indicators 
of adherence assessed, included follow-up on 
appointments, compliance to medication, dietary 
restrictions, recommended regular exercise, smoking 
cessation and alcohol cessation. Majority of the study 
participant reported that they considered all the six 
indicators to be very important. Sixty nine percent of 
the study participants reported not failing to take their 
prescribed medicines at any time which is higher 
compared with adherence rate reported by Riegel et al 
(2012).  Forgetfulness was the reason given by the 
majority of the participants for failing to take their 
medicines. 
Accessibility to medicine is an important determinant of 
adherence and it is imperative to ensure that medicines 
are accessible to those who need them. Our study 
revealed that majority of the study participants did not 
find it difficult to access medicines prescribed for them. 
Non-adherence increases the cost of healthcare (Bagchi 
et al, 2007). This could be due to poor communication 
between the healthcare provider and the patient, but in 
our study we found that 79.5% of the participants had 
been informed as to why they were taking the 
prescribed medicines. 
Majority of the patients diagnosed with CHF at KNH 
were on a diuretic with the most frequently prescribed 
diuretics being frusemide alone or in combination with 
an aldosterone receptor antagonist, invariably 
spironolactone. The other commonly used drugs in the 
treatment of CHF at KNH included beta adrenergic 
receptor antagonists, and cardiac glycosides. The most 
commonly prescribed combination at KNH was; diuretic 
+ ACE inhibitor +beta-blocker +cardiac glycoside. 
ACE inhibitors are indicated as first line therapy in 
patients with left ventricular systolic dysfunction with a 
reduced ejection fraction because they reduce both 
preload and afterload (peripheral resistance) without 
causing a reflex sympathetic activation (Swedberg et al, 
2005, Bennett and Brown 2008). ARBs are indicated in 
patients who cannot tolerate ACE inhibitors (Granger et 
al, 2003, Pfeffer et al, 2003, Maggioni et al, 2002, Cohn 
et al, 2003) and Cardiac glycosides are indicated in any 
degree of symptomatic CHF (Coletta et al, 2003). 
Diuretics are essential in symptomatic management of 
CHF especially in the presence of pulmonary congestion 
and pulmonary edema. 
Studies have shown that patients’ education is a key 
component in comprehensive CHF management. There 
is however a gap between patients receiving and 
absorbing or retaining information on self-care (Ni et al, 
1999). Other studies indicate that health literacy is 
independently related to disease knowledge, which 
underscores the need to improve patients’ knowledge of 
their chronic diseases (Gazmararian et al, 2003).  
Majority of the study participants were aware of the 
condition they suffer from, although the majority had 
suffered from the condition for less than five years. A 
small proportion had suffered for more than ten years 
and some had been hospitalized for more than seven 
times. The level of understanding of CHF was generally 
poor with only about one third of the participants 
reporting that they understood most things in respect of 
the lifestyle changes requisite to ensure that symptoms 
of CHF did not get worse.  
Telemonitoring (TM) and structured telephone support 
(STS) have been used to improve outcomes in CHF  and 
self-management programs have been shown to 
decrease readmission for CHF (Inglis et al, 2011, 
Ezekowitz et al, 2003), but there is still need for 
continuous education of both healthcare providers and 
patients (Achelrod et al, 2014). Effective 
communication is essential in management of chronic 
diseases and there is need for continuous education of 
both the health care providers and patients with respect 
to adherence and self-care in the comprehensive 
management of CHF. 
Valvular heart disease was the most common 
comorbidity among CHF patients at KNH followed by 
hypertension, anemia and diabetes mellitus. Other 
comorbidities noted included, ulcers, ischemic heart 
disease, hyperthyroidism, dilated cardiomyopathy and 
restrictive cardiomyopathy.  Ho et al, 2014 observed 
that comorbidities are common and result in increased 
hospital stay in patient with CHF. They reported anemia 
to be a common and independent prognostic factor for 
mortality, while other studies reported that renal 
failure, heart failure and anemia cause or worsen each 
other (Silverberg et al, 2005)  
The most common adverse drug effects reported in our 
study are tachycardia, skin rash, vomiting, bradycardia, 
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renal dysfunction and hyponatremia. ACE inhibitors 
cause cough and are associated with compromising the 
renal function and should be withdrawn when serum 
creatinine increases by 100%, but ARBs have been 
reported to contribute to the risk of cancer (Sipahi et al, 
2010) 
Loop diuretics cause hypokalemia, hypomagnesemia 
and hyponatremia, while potassium sparing diuretics 
are associated with hyperkalemia, and digoxin which 
has a low therapeutic index causes bradycardia, nausea 
and vomiting (Bennett and Brown 2008). On their part 
beta-blockers cause fatigue and sleep disturbances and 
affect carbohydrate metabolism and may cause 
hypoglycemia and hyperglycemia in patients with or 
without diabetes (Svensson et al, 2003). 
5. Conclusion 
Adherence to medicines among patients with CHF is 
reasonably high at KNH, but patients’ knowledge level 
about CHF was generally low. Valvular heart disease 
was the most common comorbidity while hyponatremia 
was the most prevalent electrolyte disturbance, and 
tachycardia, vomiting and rash the most common 
adverse drug effects. The study did not assess 
healthcare provider related factors that affect 
adherence.   
Continuous education of both the healthcare provider 
and the patient should be done to build a strong 
therapeutic relationship. This will improve adherence 
to medicines, improve the patient’s quality of life and 
ameliorate the economic burden to the healthcare 
system by reducing morbidity and mortality. 
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